ORAI1 and pancreatitis: The use of ORAI1 inhibitors, such as CM4620, GSK-7975A and CM_128, has been suggested as a therapeutic approach, effectively reducing cytosolic Ca2+ overload in pancreatic cells and mitigating the inflammatory response associated with pancreatitis (204, 205).